Arca
Skip to content
Tools
Tools

CSNK1E: Casein kinase I isoform epsilon

Casein kinases are operationally defined by their preferential utilization of acidic proteins such as caseins as substrates (Probable).

  • Drugs that act on it: 1
  • Approved: 1
  • In phases 1 to 3: 0
  • Sponsors: 1

Who is on it, and how far along

Every drug ChEMBL records acting on CSNK1E, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Small molecule 1

Approved1

  • Umbralisib

Phase 30

    Phase 20

      Phase 10

        The landscape

        Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials.
        DrugFurthest stageSponsorModalityActionOpen trials
        UmbralisibWithdrawnApprovedTG TherapeuticsSmall moleculeInhibitorCasein kinase I epsilon inhibitor4

        Open trials

        The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 4 in all, from ClinicalTrials.gov.
        Acalabrutinib, Umbralisib, and Ublituximab for the Treatment of Previously Untreated Mantle Cell LymphomaUmbralisibPhase 2Active, not recruitingCity of Hope Medical CenterMar 5, 2021
        Acalabrutinib, Umbralisib, and Ublituximab (AU2) In Relapsed and Untreated CLLUmbralisibPhase 2Active, not recruitingJennifer R. Brown, MD, PhDNov 12, 2020
        Combination of Pembrolizumab With TGR-1202 in Patients With Relapsed/Refractory CLL and B-cell NHLUmbralisibPhase 1Active, not recruitingUniversity of ChicagoSep 14, 2017
        Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular LymphomaUmbralisibPhase 2Active, not recruitingNational Cancer Institute (NCI)Sep 1, 2017

        Diseases most associated with it

        Open Targets association score, 0 to 1; all associations
        • Marginal zone lymphoma0.48
        • Neoplasm0.39
        • Neurodegenerative disease0.37
        • X-linked spasticity-intellectual disability-epilepsy syndrome0.33
        • Developmental and epileptic encephalopathy, 10.33
        • Hypotensive disorder0.21
        • Ovarian neoplasm0.19

        Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL4937, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. Gene name, function (UniProt P49674, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets

        Esc

        Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

        Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.